Literature DB >> 20598596

Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.

Andreia Santos1, Célia Lopes, Raquel M Marques, Irina Amorim, Jorge Ribeiro, Carlos Frias, Corália Vicente, Fátima Gärtner, Augusto de Matos.   

Abstract

Urokinase plasminogen activator (uPA) has been associated with aggressive behaviour and poor prognosis in human breast cancer, but there is no information on its expression in canine mammary tumours (CMT). uPA immunohistochemical expression was studied in 119 CMT (24 benign, 95 malignant) to investigate its relationship with clinical and histopathological parameters. Dogs with malignant mammary tumours (MMT) underwent a 2-year follow-up evaluation. MMT expressed significantly more uPA than benign tumours. In MMT, high uPA stromal expression was significantly associated with larger tumour size, high Ki-67 expression, invasive growth, high histological grade, regional lymph node metastases, development of distant metastases, and lower overall survival (OS) and disease-free survival (DFS). On the basis of these results, uPA could be considered a useful prognostic factor in dogs with MMT.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598596     DOI: 10.1016/j.tvjl.2010.05.023

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  7 in total

1.  Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.

Authors:  Cláudia Viegas; Augusto J de Matos; Liliana R Leite-Martins; Inês Viegas; Rui R F Ferreira; Hugo Gregório; Andreia A Santos
Journal:  Can J Vet Res       Date:  2020-01       Impact factor: 1.310

2.  Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.

Authors:  Sofia C Ramos; Augusto J de Matos; João Niza Ribeiro; Liliana R Leite-Martins; Rui R F Ferreira; Inês Viegas; Andreia A Santos
Journal:  Vet World       Date:  2017-08-14

3.  Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.

Authors:  John H Rossmeisl; Kelli Hall-Manning; John L Robertson; Jamie N King; Rafael V Davalos; Waldemar Debinski; Subbiah Elankumaran
Journal:  Onco Targets Ther       Date:  2017-04-12       Impact factor: 4.147

4.  Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.

Authors:  Adriana Tomoko Nishiya; Marcia Kazumi Nagamine; Ivone Izabel Mackowiak da Fonseca; Andrea Caringi Miraldo; Nayra Villar Scattone; José Luiz Guerra; José Guilherme Xavier; Mário Santos; Cristina Oliveira Massoco de Salles Gomes; Jerrold Michael Ward; Shihui Liu; Stephen Howard Leppla; Thomas Henrik Bugge; Maria Lucia Zaidan Dagli
Journal:  Toxins (Basel)       Date:  2020-03-02       Impact factor: 4.546

Review 5.  Know Thy Model: Charting Molecular Homology in Stromal Reprogramming Between Canine and Human Mammary Tumors.

Authors:  Enni Markkanen
Journal:  Front Cell Dev Biol       Date:  2019-12-17

6.  Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study.

Authors:  Andreia A Santos; Célia C Lopes; Jorge R Ribeiro; Liliana R Martins; Joana C Santos; Irina F Amorim; Fátima Gärtner; Augusto J Matos
Journal:  BMC Vet Res       Date:  2013-01-04       Impact factor: 2.741

7.  Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells.

Authors:  Jonathan Mackowiak da Fonseca; Ivone Izabel Mackowiak da Fonseca; Marcia Kazumi Nagamine; Cristina de Oliveira Massoco; Adriana Tomoko Nishiya; Jerrold Michael Ward; Shihui Liu; Stephen Howard Leppla; Thomas Henrik Bugge; Maria Lucia Zaidan Dagli
Journal:  Toxins (Basel)       Date:  2020-09-24       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.